Literature DB >> 2027094

Psychiatric morbidity in the relatives of patients with DSM-III schizophreniform disorder: comparisons with the relatives of schizophrenic and bipolar disorder patients.

A E Pulver1, C H Brown, P S Wolyniec, J A McGrath, D Tam.   

Abstract

Risks for psychiatric disorders (RDC) among first degree relatives of DSM-III schizophreniform, bipolar, and schizophrenic probands obtained from an epidemiologic sample using family history methods were examined. The relatives of the schizophreniform probands differed from the relatives of the schizophrenic and bipolar probands. The relatives of schizophreniform probands had significantly higher rates of affective illnesses (with the exception of bipolar illness) than the relatives of schizophrenic probands, and they had a significantly higher rate of psychotic affective disorders than the relatives of the bipolar probands.

Entities:  

Mesh:

Year:  1991        PMID: 2027094     DOI: 10.1016/0022-3956(91)90013-z

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  A follow-up and family study of DSM-III-R schizophreniform disorder with good prognostic features.

Authors:  F Benazzi; M Mazzoli; E Rossi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

2.  Follow-up and family study of postpartum psychoses. Part IV: Schizophreniform psychoses and brief reactive psychoses: lack of nosological relation to schizophrenia.

Authors:  J Schöpf; B Rust
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 3.  Outcome of schizophreniform disorder.

Authors:  Franco Benazzi
Journal:  Curr Psychiatry Rep       Date:  2003-07       Impact factor: 5.285

4.  Work environment and schizophrenia: an extension of the arousal hypothesis to occupational self-selection.

Authors:  C Muntaner; A E Pulver; J McGrath; W W Eaton
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1993-10       Impact factor: 4.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.